All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Cytogenetic abnormalities in AML
ASH 2017 | MRD risk-adapted therapy in AML
At the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, the AGP attended an oral session which focused on risk-adapted therapies in Acute Myeloid Leukemia (AML)
MRD directed treatment in AML - Oral abstract session at the 22nd Congress of the EHA
There were a range of talks discussing the importance of the inclusion of MRD detection in risk-adapted treatment strategies for patients with AML.
Subscribe to get the best content related to AML delivered to your inbox